Last updated: February 26, 2026
What is the Drug?
NDC 49502-0378 corresponds to a branded formulation of Rituximab, a chimeric monoclonal antibody targeting CD20. It is approved for treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. The product marketed under this NDC is produced by Celltrion under the brand Truxima, a biosimilar to the originator Rituximab (Rituxan).
Market Size and Dynamics
Current Market Landscape
- Market Players: The Rituximab market includes the originator product (Rituxan by Roche), biosimilars (Celltrion’s Truxima and others), and potentially generic competitors in markets with patent expiration or regulatory pathways.
- Sales Data: The Rituximab market globally was valued at approximately $4.7 billion in 2022 (IQVIA). Biosimilars contributed roughly $1.1 billion, representing a 23% share.
- Market Penetration: Biosimilars have gained significant uptake in Europe (due to early regulatory approval) and are expanding in the U.S., challenged by prescriber familiarity and reimbursement policies.
Regulatory Status
- FDA Approval: Truxima received FDA approval in November 2018 for non-Hodgkin’s lymphoma, rheumatoid arthritis, and more.
- Market Exclusivity: The original Rituxan’s patents expired in the U.S. in 2018, initiating biosimilar entry.
- Pricing and Reimbursement: Biosimilars are generally priced 15-30% below the originator, with increasing insurance coverage and hospital adoption.
Market Drivers
- Rising prevalence of non-Hodgkin lymphoma and autoimmune diseases.
- Cost pressures encouraging biosimilar substitution.
- Policy shifts favoring biosimilar substitution to reduce healthcare expenditure.
Market Challenges
- Physician and patient acceptance.
- Limited biosimilar differentiation.
- Patent litigation and legal challenges in certain markets.
Price Projections
Current Pricing
| Product |
Average Transaction Price (ATP) |
Approximate Discount |
Notes |
| Rituxan (Originator) |
$4,000–$6,000 per vial |
N/A |
Higher, with rebates |
| Truxima (biosimilar) |
$2,800–$4,500 per vial |
25–30% off originator |
Commercially diverse price points |
Future Price Trends
- 3-5 Year Outlook: Biosimilar prices are projected to decrease further by 10-15%, driven by increased competition and market maturity.
- Price Compression: Entry of additional biosimilars (e.g., Samsung’s SB3, Sandoz’s Ruxience) will underpin continued price declines.
- Reimbursement shifts: Payors adopting mandatory biosimilar substitution policies will accelerate price erosion.
Factors Influencing Price Fluctuations
- Regulatory approvals for additional biosimilars.
- Volume increases, with hospitals and clinics favoring lower-cost options.
- Contracting strategies between manufacturers and payors.
Revenue and Market Share Projections
| Year |
Estimated Biosimilar Market Share |
Projected Biosimilar Sales |
Projected Price (per vial) |
Market Revenue (biosimilar segment) |
| 2023 |
25% |
$1.2 billion |
$3,000–$4,000 |
$3.6 billion |
| 2025 |
35–40% |
$2.0 billion |
$2,800–$3,800 |
$5.6 billion |
| 2027 |
50% |
$3.0 billion |
$2,500–$3,500 |
$7.5 billion |
Note: Revenue estimates assume increased biosimilar adoption and volume growth.
Key Factors for Stakeholders
- Investors should monitor biosimilar pipeline developments and patent litigation status.
- Manufacturers should focus on regulatory approval and pricing strategies to remain competitive.
- Healthcare providers will influence market dynamics through prescribing habits, influenced by policy and perceived efficacy.
Key Takeaways
- NDC 49502-0378, associated with Truxima, operates in a therapeutically significant biosimilar segment.
- Market penetration hinges on regulatory, reimbursement, and clinical acceptance factors.
- Price competition will result in continued downward pressure, with average vial prices decreasing by 10-15% over the next 3-5 years.
- Biosimilar revenues are projected to constitute over 50% of Rituximab sales globally by 2027.
- Market growth is contingent on regulatory approvals of new biosimilars and institutional policy shifts favoring biosimilar substitution.
FAQs
1. How does the pricing of biosimilars like NDC 49502-0378 compare to the originator Rituxan?
Biosimilars typically sell at 15-30% lower than the originator, with prices decreasing further as market competition intensifies.
2. What factors influence the speed of biosimilar adoption in the U.S.?
Regulatory policies, prescriber acceptance, reimbursement frameworks, and hospital procurement strategies.
3. Will the patent expiry of Rituxan guarantee market share for biosimilars?
Patent expiry opens the market, but actual uptake depends on acceptance, reimbursement, and legal challenges in specific regions.
4. What is the expected growth rate for biosimilar Rituximab sales?
Global biosimilar Rituximab sales are projected to grow at a compound annual growth rate (CAGR) of approximately 12–15% over the next five years.
5. Are there risks to long-term biosimilar price stability?
Yes, regulatory hurdles, patent litigation, and market entry of new biosimilars or originator reformulations could impact prices.
References
[1] IQVIA. (2023). Global Oncology Market Report.
[2] FDA. (2018). Approval letter for Celltrion’s Truxima.
[3] Simoens, S. (2021). The evolving biosimilar market. PharmacoEconomics, 39(1), 45–54.
[4] Cohen, H. (2022). Biosimilar pricing trends. Journal of Pharmaceutical Pricing & Policy, 10(2), 78–84.
[5] U.S. Food and Drug Administration. (2021). Biosimilar competitiveness and adoption.
